| Kristen R Stakelin, MD | |
|
1138 Lexington Rd, Ste 290, Georgetown, KY 40324-9672 | |
| (502) 863-0721 | |
| (502) 863-6104 |
| Full Name | Kristen R Stakelin |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 27 Years |
| Location | 1138 Lexington Rd, Georgetown, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235138348 | NPI | - | NPPES |
| 64017395 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 34091 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kentucky Hospital | Lexington, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kentucky Medical Services Foundation, Inc | 5698689909 | 806 |
News Archive
AMRI today announced that its board of directors has approved a new share repurchase program of up to $10 million. Under the program, the company is authorized to repurchase outstanding shares of its Common Stock in the open market or in private transactions. Shares may be repurchased from time to time and in such amounts as market conditions warrant, subject to price ranges set by management and regulatory considerations.
Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital.
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.
New research published Online First in The Lancet suggests that drug-resistant HIV has been increasing in parts of Sub-Saharan Africa since the roll-out of antiretroviral therapy (ART) nearly a decade ago.
› Verified 6 days ago
| Entity Name | Kentucky Medical Services Foundation, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326091448 PECOS PAC ID: 5698689909 Enrollment ID: O20031119000300 |
News Archive
AMRI today announced that its board of directors has approved a new share repurchase program of up to $10 million. Under the program, the company is authorized to repurchase outstanding shares of its Common Stock in the open market or in private transactions. Shares may be repurchased from time to time and in such amounts as market conditions warrant, subject to price ranges set by management and regulatory considerations.
Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital.
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.
New research published Online First in The Lancet suggests that drug-resistant HIV has been increasing in parts of Sub-Saharan Africa since the roll-out of antiretroviral therapy (ART) nearly a decade ago.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristen R Stakelin, MD 1138 Lexington Rd, Ste 290, Georgetown, KY 40324-9672 Ph: (502) 863-0721 | Kristen R Stakelin, MD 1138 Lexington Rd, Ste 290, Georgetown, KY 40324-9672 Ph: (502) 863-0721 |
News Archive
AMRI today announced that its board of directors has approved a new share repurchase program of up to $10 million. Under the program, the company is authorized to repurchase outstanding shares of its Common Stock in the open market or in private transactions. Shares may be repurchased from time to time and in such amounts as market conditions warrant, subject to price ranges set by management and regulatory considerations.
Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital.
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.
New research published Online First in The Lancet suggests that drug-resistant HIV has been increasing in parts of Sub-Saharan Africa since the roll-out of antiretroviral therapy (ART) nearly a decade ago.
› Verified 6 days ago
Dr. Kent Edward Taylor, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1140 Lexington Rd, Suite 202, Georgetown, KY 40324 Phone: 502-868-1100 Fax: 502-868-5612 | |
Dr. Matthew C Birdwhistell, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1138 Lexington Rd, Suite 290, Georgetown, KY 40324 Phone: 502-863-0721 Fax: 502-863-6104 | |
Robert Craig Martin, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1138 Lexington Rd, Suite 290, Georgetown, KY 40324 Phone: 502-863-0721 Fax: 502-863-6104 | |
Dr. Hugh Harrison Loeffler, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1138 Lexington Rd Ste 290, Georgetown, KY 40324 Phone: 502-863-0721 Fax: 502-863-6104 | |
Naba Saeed, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1140 Lexington Rd, Georgetown, KY 40324 Phone: 502-868-1100 | |
Benjamin P Lyon, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1138 Lexington Rd, Ste 290, Georgetown, KY 40324 Phone: 502-863-0721 Fax: 502-863-6104 |